Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
2,5-Dimethoxy-4-ethylamphetamine (DOET) is a synthetic psychedelic drug belonging to the phenethylamine and amphetamine chemical classes. It is part of the DOx family of substituted amphetamines and is structurally related to mescaline and DOM. DOET acts primarily as an agonist at serotonin 5‑HT₂A receptors in the brain, which mediates its hallucinogenic and entheogenic effects. The compound produces long-lasting psychedelic effects with an onset of action between one to three hours and a duration that can extend up to twenty hours. It has been described as having antidepressant and cognitive-enhancing properties in addition to its primary psychedelic activity[1][5]. The toxicity profile of DOET remains largely unknown.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 2,5-Dimethoxy-4-ethylamphetamine.